- Home
- SLQT vs CRGX Comparison
SLQT vs CRGX Comparison
Compare SLQT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLQT
- CRGX
- Stock Information
- Founded
- SLQT 1999
- CRGX 2021
- Country
- SLQT United States
- CRGX United States
- Employees
- SLQT N/A
- CRGX N/A
- Industry
- SLQT Specialty Insurers
- CRGX
- Sector
- SLQT Finance
- CRGX
- Exchange
- SLQT Nasdaq
- CRGX Nasdaq
- Market Cap
- SLQT 386.9M
- CRGX 190.0M
- IPO Year
- SLQT 2020
- CRGX 2023
- Fundamental
- Price
- SLQT $2.44
- CRGX $4.59
- Analyst Decision
- SLQT Hold
- CRGX Hold
- Analyst Count
- SLQT 2
- CRGX 7
- Target Price
- SLQT $3.38
- CRGX $5.33
- AVG Volume (30 Days)
- SLQT 968.0K
- CRGX 1.9M
- Earning Date
- SLQT 05-12-2025
- CRGX 08-11-2025
- Dividend Yield
- SLQT N/A
- CRGX N/A
- EPS Growth
- SLQT N/A
- CRGX N/A
- EPS
- SLQT N/A
- CRGX N/A
- Revenue
- SLQT $1,488,701,000.00
- CRGX N/A
- Revenue This Year
- SLQT $17.72
- CRGX $57.81
- Revenue Next Year
- SLQT $13.05
- CRGX N/A
- P/E Ratio
- SLQT N/A
- CRGX N/A
- Revenue Growth
- SLQT 20.41
- CRGX N/A
- 52 Week Low
- SLQT $1.62
- CRGX $3.00
- 52 Week High
- SLQT $6.86
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- SLQT 53.19
- CRGX 61.56
- Support Level
- SLQT $2.35
- CRGX $4.32
- Resistance Level
- SLQT $2.69
- CRGX $4.63
- Average True Range (ATR)
- SLQT 0.13
- CRGX 0.16
- MACD
- SLQT 0.03
- CRGX 0.04
- Stochastic Oscillator
- SLQT 52.83
- CRGX 76.44
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.